Alan P. Skarbnik, MD, Novant Health Cancer Institute
Advertisement
Articles by Alan P. Skarbnik, MD, Novant Health Cancer Institute
Advertisement
Latest Updated Articles
Therapeutic Sequencing in Relapsed/Refractory CLLJanuary 8th 2021
Allogeneic Transplantation for CLLJanuary 8th 2021
Frontline CLL Treatment: Addressing Unmet NeedsJanuary 8th 2021
Selecting Frontline Therapy to Treat CLLJanuary 8th 2021
Frontline CLL Treatment With Fixed-Duration RegimensJanuary 8th 2021
Minimal Residual Disease in CLLJanuary 8th 2021
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Dostarlimab for dMMR/MSI-H Locally Advanced Rectal Cancer
2
FDA Clears TumorSight Risk, an MRI-Derived AI Recurrence Tool for HR+, HER2– Breast Cancer
3
Vilamakitug Meets OS Threshold in Phase 1/2 Refractory mCRC Trial
4
Dr Cercek on the FDA Approval of Dostarlimab for dMMR/MSI-H Locally Advanced Rectal Cancer
5